Neurometabolic Diseases Lab

  • Increase font size
  • Default font size
  • Decrease font size
Home On the News Facebook/ STOP ALD FOUNDATION

Facebook/ STOP ALD FOUNDATION

E-mail Print PDF

Important and exciting update for patients with AMN:

Biomarker Identification, Safety, and Efficacy of High-Dose Antioxidants for Adrenomyeloneuropathy: a Phase II Pilot Study

Ver el artículo en el link:


Last Updated on Monday, 27 January 2020 17:25  

View My Stats